Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Trans-Atlantic Technology (TAT) is a specialized medical technology company focused on the distribution and support of advanced extracorporeal shock wave therapy (ESWT) and lithotripsy systems. The company serves as a primary partner for Medispec in the United States, providing non-invasive solutions for urological and orthopedic conditions such as kidney stones and chronic tendonitis. Their product portfolio includes the Orthospec and Urospec systems, which utilize shock wave technology to treat musculoskeletal pain and urinary calculi without surgery. Beyond equipment sales, TAT provides comprehensive clinical training, technical support, and maintenance services to healthcare providers across North America.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Trans Atlantic Technology.